Other Affiliated Sites
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Corporate Governance
2025.12.17
智信：对外担保管理制度
2025.12.17
智信：内幕信息知情人登记管理制度
2024.04.16
智信：关于对深圳证券交易所2023年年报问询函回复的公告
2024.03.29
智信：监事会对《董事会关于2023年度内部控制审计报告带强调事项段的无保留审计意见涉及事项的专项说明》的意见
2024.03.29
智信：关于对会计师事务所2023年度履职情况评估报告
2024.03.29
智信：独立董事2023年度述职报告（易铭）
2024.03.29
智信：独立董事2023年度述职报告（王肈辉）
2024.03.29
智信：独立董事2023年度述职报告（吕川）
2024.03.29
智信：独立董事2023年度述职报告（黄鹏）
2024.03.29
智信：独立董事2023年度述职报告（陈俊发）
第一页
上一页
1
2
3
4
5
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.
站点地图
